LR Health & Beauty published its final annual report for 2025. Included in the report were preliminary full-year 2025 sales totals, which reached $319 million, down from $333 million in 2024. EBITDA for 2025 is reported at $19 million, compared to $31 million in 2024. Normalized EBITDA for the year was approximately $25.9 million.
LR stated that it is prioritizing in-house production and investing more than $2 million in a new, high-performance production line that will centralize the manufacture of its 5in1 product category at its Ahlen site. The new production facility is expected to have an annual capacity of up to 40 million units and will allow the company to expand future product innovations in the modern nutritional supplements category.
“The 2026 financial year is a transitional year for LR, during which we have laid the groundwork – both financially and strategically – for sustainable business growth and performance,” said Jörg Körfer, LR Health & Beauty SE CEO. “The newly established financing structure gives us the momentum we need to continue to consistently pursue the initiatives we have launched in production, logistics and sales in the second half of the year. In this context, we are committed to working closely with our partners and are continuing to expand these relationships internationally.”
